Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188928
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bastos Oreiro, Mariana | - |
dc.contributor.author | Gutiérrez, Antonio | - |
dc.contributor.author | Reguera, Juan Luís | - |
dc.contributor.author | Iacoboni, Gloria | - |
dc.contributor.author | López Corral, Lucía | - |
dc.contributor.author | Terol, María José | - |
dc.contributor.author | Ortíz Maldonado, Valentín | - |
dc.contributor.author | Sanz, Jaime | - |
dc.contributor.author | Guerra Dominguez, Luisa | - |
dc.contributor.author | Bailen, Rebeca | - |
dc.contributor.author | Mussetti, Alberto | - |
dc.contributor.author | Abrisqueta Costa, Pau | - |
dc.contributor.author | Hernani, Rafael | - |
dc.contributor.author | Luzardo, Hugo | - |
dc.contributor.author | Sancho, Juan Manuel | - |
dc.contributor.author | Delgado Serrano, Javier | - |
dc.contributor.author | Salar, Antonio | - |
dc.contributor.author | Grande, Carlos | - |
dc.contributor.author | Bento, Leyre | - |
dc.contributor.author | González de Villambrosía, Sonia | - |
dc.contributor.author | García Belmonte, Daniel | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Pérez Martínez, Antonio | - |
dc.contributor.author | Barba, Pere | - |
dc.contributor.author | Kwon, Mi | - |
dc.contributor.author | Martín García Sancho, Alejandro | - |
dc.date.accessioned | 2022-09-12T10:41:14Z | - |
dc.date.available | 2022-09-12T10:41:14Z | - |
dc.date.issued | 2022-07-12 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/188928 | - |
dc.description.abstract | Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p <= 0.001) and overall survival (OS) (median of 15 vs. 8 months, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001] for PFS, and 0.45 [(95% CI: 0.31-0.64)] for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 versus 2.8 months, respectively, p = 0.027) and OS (58% versus 42% at 12 months, respectively, p = 0.048) than tisa-cel. These differences were maintained in the multivariable analysis. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.855730 | - |
dc.relation.ispartof | Frontiers in Immunology, 2022, vol. 13, p. 855730 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2022.855730 | - |
dc.rights | cc by (c) Bastos Oreiro, Mariana et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Teràpia cel·lular | - |
dc.subject.classification | Cèl·lules B | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Cellular therapy | - |
dc.subject.other | B cells | - |
dc.title | Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-08-16T11:31:22Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35911769 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-855730.pdf | 1.04 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License